ARTICLE | Product Development
Riptide peptide turns TAMs proinflammatory
Riptide unveils preclinical pancreatic cancer data, shows candidate reprograms TAMs
February 18, 2020 8:21 PM UTC
Updated on Feb 19, 2020 at 1:42 AM UTC
Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory.
Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum as a way to simultaneously release the brakes and rev up the gas for antitumor immunity (see "Flipping the Switch in Immuno-oncology")...
BCIQ Company Profiles